Compare Cytokinetics Inc (CYTK) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Cytokinetics Inc trades at $62.64 (market cap $8.62B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.66 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 19.5× Cytokinetics Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| CYTK | VWO | |
|---|---|---|
Market Cap | $8.62B | $168.50B |
Volume | 2,594,626 | 9,650,999 |
Sector | Health | — |
52-Week High | $87.26 | $61.44 |
52-Week Low | $54.76 | $52.42 |
Typical Hold Time | 19 Days | 134 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
VWO trades at $59.77, down 0.13% on the day, with a bearish technical signal from moving averages and key indicators like ADX signaling selling pressure. Recent news highlights a divergence in performance, with AI-driven strength in Taiwan holdings like TSMC offset by economic weakness in China. The ETF's focus on over 6,000 emerging-market stocks provides diversification but faces concentration risks.
The outlook is cautious due to mixed technicals and regional economic headwinds, particularly in China. Opportunities exist from AI infrastructure growth, but risks include currency volatility and reliance on a few key markets. Investors should weigh the ETF's low expense ratio against emerging-market volatility and slowing growth in major constituents.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
